Catalyst Pharmaceuticals
Steve Miller is an accomplished professional in the pharmaceutical industry, currently serving as the Chief Operating Officer at Catalyst Pharmaceutical Partners, Inc. since October 2009, where responsibilities include overseeing all company operations. Previously, Steve held the role of Chief Scientific Officer at the same company, focusing on new drug development. Prior to this, Steve was the VP of Pharmaceutical Development at Catalyst Pharmaceuticals from April 2007 to October 2009, managing new product development activities. Steve's extensive experience also includes positions as Executive Director at Watson Pharmaceuticals and Watson Laboratories, and Group Leader at Baxter Healthcare. Steve holds a Ph.D. in Chemistry from the University of Miami and a BS in Chemistry from the University of Maryland.
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.